Cells can be taken from the patient directly (autologous MSCs) or from a healthy donor (allogeneic MSCs). The company is focused on working with allogeneic MSCs because these cells can be made available to many more patients than autologous cells.

​

Allogeneic MSCs are made to express E-selectin by using a known gene therapy vector to bring a transgene encoding the E-selectin into the cell.  Once transferred and expressed we refer to these engineered cells as “supercharged” due to better healing properties observed in animal studies.

 

Supercharged MSCs provide an adhesive foundation for regeneration and may also promote healing through robust paracrine mechanisms that are being elucidated.